Eryderm 2% Topical Solution
Erythromycin solution
20mg/ml
Abbot Laboratories
| Pack size | 60ml |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | CITY MEDICAL STORE |
| Retail Price | 40.50 AED |
Indications
Eryderm 2% Topical Solution is used for:
Acne
Adult Dose
Topical/Cutaneous
Acne
Adult: Apply onto affected areas 1-2 times daily. Discontinue treatment if condition worsens or if there is no improvement after 6-8 wk of continuous usage.
Max duration: 6 mth.
Child Dose
Safety and efficacy not established
Renal Dose
Administration
Apply to affected areas after skin is thoroughly washed and patted dry
Contra Indications
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Precautions
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
Lactation: Unknown if excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy Category: B
Lactation: Unknown if excreted in breast milk; use with caution
Interactions
Rhabdomyolysis w/ or w/o renal impairment w/ HMG-CoA reductase inhibitors (e.g. simvastatin). Increased risk of colchicine toxicity. Increased sedation w/ triazolobenzodiazepines and related benzodiazepines (e.g. alprazolam, midazolam). Theophylline may decrease and cimetidine may increase erythromycin concentration. Hypotension, bradyarrhythmia and lactic acidosis w/ Ca channel blockers (e.g. verapamil, amlodipine, diltiazem). Increased systemic exposure of sildenafil. Increased or prolonged adverse effects w/ ciclosporin, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine and bromocriptine. Increased risk of digoxin toxicity. Increased bleeding w/ oral anticoagulants.
Potentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.
Adverse Effects
Side effects of Erythromycin solution :
Contact sensitization, Dryness, Erythema, Skin irritation, Skin tenderness
Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
Mechanism of Action
Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
Note
Eryderm 2% 20mg/ml Topical Solution manufactured by Abbot Laboratories. Its generic name is Erythromycin solution. Eryderm 2% is availble in United Arab Emirates.
Farmaco UAE drug index information on Eryderm 2% Topical Solution is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.